Bivalirudin provides increasing benefit with decreasing renal function: A meta-analysis of randomized trials

Derek P. Chew, Deepak L. Bhatt, William Kimball, Timothy D Henry, Peter Berger, Peter A. McCullough, Frederick Feit, John A. Bittl, A. Michael Lincoff

Research output: Contribution to journalArticlepeer-review

94 Scopus citations


Chronic kidney disease is associated with an increased risk of ischemic and bleeding events after percutaneous coronary intervention (PCI). The direct thrombin inhibitor bivalirudin reduces these combined events. We sought to assess whether this benefit was influenced by renal function. A meta-analysis of 3 randomized trials (n = 5,035) comparing bivalirudin with heparin during PCI, stratified by estimated creatinine clearance using the Cockcroft-Gault equation (>90 [n = 1,578], 90 to 60 [n = 2,163], 59 to 30 [n = 1,255], and <30 ml/min [n = 39]), was conducted. The composite end points of death, myocardial infarction or revascularization, hemorrhage, and combined ischemic or bleeding events were assessed. A common odds ratio for each creatinine clearance strata was estimated with a random-effects model. The interaction between renal impairment and benefit from bivalirudin was assessed. Adverse ischemic and bleeding events increased with decreasing renal function. The relative benefit of bivalirudin with respect to ischemic and bleeding events was maintained within each stratum. The absolute benefit in terms of ischemic and bleeding complications increased with decreasing creatinine clearance (normal 2.2%, mild 5.8%, moderate 7.7%, severe 14.4%; p trend <0.001, interaction p = 0.044). Renal dysfunction remains a prevalent risk factor for ischemic and bleeding events in patients who undergo PCI. Bivalirudin provides greater absolute benefit in patients with impaired renal function.

Original languageEnglish (US)
Pages (from-to)919-923
Number of pages5
JournalAmerican Journal of Cardiology
Issue number8
StatePublished - Oct 15 2003


Dive into the research topics of 'Bivalirudin provides increasing benefit with decreasing renal function: A meta-analysis of randomized trials'. Together they form a unique fingerprint.

Cite this